Core Company Developments - EUDA Health Holdings Limited has launched a nationwide stem cell extraction, cryogenic storage, and clinical delivery platform in China, partnering with Shenzhen Inno Immune Co., Ltd. and Wuhan Kaien Hospital to expand its clinical and logistics network [1] - The platform represents a significant advancement in EUDA's stem cell strategy, enhancing capabilities in cell extraction, processing, cryogenic storage, logistics, and clinical application [1] Platform Design Principles - The platform is built on three core principles: centralized processing with decentralized access, long-term cell preservation for future clinical use, and integration with longevity medicine [2] Infrastructure and Capacity - Shenzhen Inno Immune Co., Ltd. serves as the primary cell processing and cryogenic storage hub in Southern China, with an initial capacity for approximately 50,000 patient cell units [3] - Wuhan Kaien Hospital is designated as the Central China clinical and longevity flagship, with a planned capacity to support around 200,000 patient cell units, integrating various health management services [4] Clinical Access and Logistics - EUDA collaborates with Guangdong Wanhai Cell Biotechnology Co., Ltd. and Shunfeng Cold Chain Logistics Co., Ltd. to establish a nationwide clinical access layer and ensure regulated transport of biological materials [6][8] - The integrated structure allows for stem cell extraction at local clinics, with subsequent processing and storage at designated facilities, ensuring quality control and scalability [8] Strategic Vision - The CEO of EUDA emphasized the transformation of regenerative medicine access in China through a coordinated national system that connects extraction, storage, logistics, and clinical delivery [9] - EUDA aims to lead the non-invasive and preventive healthcare market in Asia, addressing the healthcare needs of over 1.8 billion people in a rapidly aging population [10]